Skip to main content

Advertisement

SpringerLink
Log in

Current Management of Liver Metastasis From Colorectal Cancer

  • Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Purpose of Review

To describe the main components of modern treatment for colorectal cancer (CRC) metastatic to the liver.

Recent Findings

Liver metastasis occurs in 50–60% of patients with CRC, and surgery is the only potentially curative treatment. Surgery should be performed where a complete (R0) resection of all radiologically visible metastases is possible. The presence of extra-hepatic disease no longer precludes liver metastectomy, and combined metastectomy in the liver and the extra-hepatic site can result in acceptable long-term survival. Peri-operative chemotherapy significantly improves PFS and DFS, but not OS. Modern cytotoxic regimens can convert a significant percentage of unresectable patients to resectable status, and the addition of biologic agents can increase the rate of conversion. Several local treatment modalities serve as alternatives, or sometimes as adjuncts, to resection of CRC liver metastasis and systemic chemotherapy.

Summary

The modern approach to CRC with liver metastasis combines surgery, modern cytotoxic and biologic agents, and modern technologies in the field of ablation, radiation, and endovascular access. The result is that long-term survival, and even cure, is now possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212–21. https://doi.org/10.1016/j.ejca.2006.04.012.

    Article  PubMed  Google Scholar 

  2. Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 2006;6(3):202–7. https://doi.org/10.3816/CCC.2006.n.036.

    Article  CAS  PubMed  Google Scholar 

  3. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15(3):938–46. https://doi.org/10.1200/JCO.1997.15.3.938.

    Article  CAS  PubMed  Google Scholar 

  4. Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol. 2007;14(2):766–70. https://doi.org/10.1245/s10434-006-9146-1.

    Article  PubMed  Google Scholar 

  5. Hayashi M, Inoue Y, Komeda K, Shimizu T, Asakuma M, Hirokawa F, et al. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg. 2010;10(1):27. https://doi.org/10.1186/1471-2482-10-27.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Stang R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343(8910):1405–10. https://doi.org/10.1016/S0140-6736(94)92529-1.

    Article  Google Scholar 

  7. Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg. 1995;82(10):1397–400. https://doi.org/10.1002/bjs.1800821034.

    Article  CAS  PubMed  Google Scholar 

  8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18; discussion 318-21. https://doi.org/10.1097/00000658-199909000-00004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66. https://doi.org/10.1097/00000658-200206000-00002.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132(5):505–10; discussion 511. https://doi.org/10.1001/archsurg.1997.01430290051008.

    Article  CAS  PubMed  Google Scholar 

  11. Norstein J, Silen W. Natural history of liver metastases from colorectal carcinoma. J Gastrointest Surg. 1997;1(5):398–407. https://doi.org/10.1016/S1091-255X(97)80126-6.

    Article  CAS  PubMed  Google Scholar 

  12. Nikfarjam M, Shereef S, Kimchi ET, Gusani NJ, Jiang Y, Avella DM, et al. Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol. 2009;16(7):1860–7. https://doi.org/10.1245/s10434-008-0225-3.

    Article  PubMed  Google Scholar 

  13. Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141(5):460–6; discussion 466-7. https://doi.org/10.1001/archsurg.141.5.460.

    Article  PubMed  Google Scholar 

  14. Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197(6):728–36. https://doi.org/10.1016/j.amjsurg.2008.04.013.

    Article  PubMed  Google Scholar 

  15. Lee WS, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol. 2008;42(8):945–9. https://doi.org/10.1097/MCG.0b013e318064e752.

    Article  PubMed  Google Scholar 

  16. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80. https://doi.org/10.1200/JCO.2007.11.0833.

    Article  PubMed  Google Scholar 

  17. Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003;12(1):165–92. https://doi.org/10.1016/S1055-3207(02)00091-1.

    Article  PubMed  Google Scholar 

  18. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–22, discussion 722-4. https://doi.org/10.1097/01.sla.0000160703.75808.7d.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Nuzzo G, Giuliante F, Ardito F, Vellone M, Giovannini I, Federico B, et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery. 2008;143(3):384–93. https://doi.org/10.1016/j.surg.2007.09.038.

    Article  PubMed  Google Scholar 

  20. de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248(4):626–37. https://doi.org/10.1097/SLA.0b013e31818a07f1.

    PubMed  Google Scholar 

  21. Shirabe K, Takenaka K, Gion T, Fujiwara Y, Shimada M, Yanaga K, et al. Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin. Br J Surg. 1997;84(8):1077–80. https://doi.org/10.1002/bjs.1800840810.

    Article  CAS  PubMed  Google Scholar 

  22. Are C, Gonen M, Zazzali K, Dematteo RP, Jarnagin WR, Fong Y, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg. 2007;246(2):295–300. https://doi.org/10.1097/SLA.0b013e31811ea962.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19(1):59–71. https://doi.org/10.1007/BF00316981.

    Article  CAS  PubMed  Google Scholar 

  24. Hamady ZZ, Cameron IC, Wyatt J, Prasad RK, Toogood GJ, Lodge JP. Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1cm rule. Eur J Surg Oncol. 2006;32(5):557–63. https://doi.org/10.1016/j.ejso.2006.02.001.

    Article  CAS  PubMed  Google Scholar 

  25. Figueras J, Burdio F, Ramos E, Torras J, Llado L, Lopez-Ben S, et al. Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections. Ann Oncol. 2007;18(7):1190–5. https://doi.org/10.1093/annonc/mdm106.

    Article  CAS  PubMed  Google Scholar 

  26. DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, Fong Y. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg. 2000;4(2):178–84. https://doi.org/10.1016/S1091-255X(00)80054-2.

    Article  CAS  PubMed  Google Scholar 

  27. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80. https://doi.org/10.1245/s10434-006-9045-5.

    Article  PubMed  Google Scholar 

  28. Headrick JR, Miller DL, Nagorney DM, Allen MS, Deschamps C, Trastek VF, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg. 2001;71(3):975–9; discussion 979-80. https://doi.org/10.1016/S0003-4975(00)02522-4.

    Article  CAS  PubMed  Google Scholar 

  29. Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007;205(2):231–8. https://doi.org/10.1016/j.jamcollsurg.2007.04.039.

    Article  PubMed  Google Scholar 

  30. Pulitano C, Bodingbauer M, Aldrighetti L, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011;18(5):1380–8. https://doi.org/10.1245/s10434-010-1459-4.

    Article  PubMed  Google Scholar 

  31. Carpizo DR, Are C, Jarnagin W, Dematteo R, Fong Y, Gönen M, et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol. 2009;16(8):2138–46. https://doi.org/10.1245/s10434-009-0521-6.

    Article  PubMed  Google Scholar 

  32. Klaver YL, Leenders BJ, Creemers GJ, et al. Addition of biological therapies to palliative chemotherapy prolongs survival in patients with peritoneal carcinomatosis of colorectal origin. Am J Clin Oncol. 2013;36(2):157–61. https://doi.org/10.1097/COC.0b013e3182438c55.

    Article  CAS  PubMed  Google Scholar 

  33. •• Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. A landmark randomized trial that showed that cytoreduction followed by HIPEC improves survival in patients with peritoneal carcinomatosis of colorectal origin. https://doi.org/10.1245/s10434-008-9966-2.

    Article  PubMed  Google Scholar 

  34. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24(24):4011–9. https://doi.org/10.1200/JCO.2006.07.1142.

    Article  PubMed  Google Scholar 

  35. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23(28):7125–34. https://doi.org/10.1200/JCO.2005.08.722.

    Article  PubMed  Google Scholar 

  36. Adam R, de Haas RJ, Wicherts DA, Aloia TA, Delvart V, Azoulay D, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol. 2008;26(22):3672–80. https://doi.org/10.1200/JCO.2007.15.7297.

    Article  PubMed  Google Scholar 

  37. Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int. 2009;29(1):89–102. https://doi.org/10.1111/j.1478-3231.2008.01845.x.

    Article  PubMed  Google Scholar 

  38. Nagashima I, Takada T, Matsuda K, Adachi M, Nagawa H, Muto T, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepato-Biliary-Pancreat Surg. 2004;11(2):79–83.

    Article  Google Scholar 

  39. •• Roberts KJ, White A, Cockbain A, Hodson J, Hidalgo E, Toogood GJ, et al. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br J Surg. 2014;101(7):856–66. A study that assessed the performance of several score systems in predicting DFS and DSS, and found that none does so with sufficient discriminatory accuracy. https://doi.org/10.1002/bjs.9471.

    Article  CAS  PubMed  Google Scholar 

  40. Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep. 2009;11(3):200–8. https://doi.org/10.1007/s11912-009-0029-z.

    Article  PubMed  Google Scholar 

  41. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

  42. Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005;23(34):8713–6. https://doi.org/10.1200/JCO.2005.04.4222.

    Article  PubMed  Google Scholar 

  43. Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg. 2010;145(4):340–5; discussion 345. https://doi.org/10.1001/archsurg.2010.41.

    Article  PubMed  Google Scholar 

  44. van Kessel CS, Buckens CF, van den Bosch MA, et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19(9):2805–13. https://doi.org/10.1245/s10434-012-2300-z.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Nagakura S, Shirai Y, Suda T, Hatakeyama K. Multiple repeat resections of intra- and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases. World J Surg. 2002;26(2):141–7. https://doi.org/10.1007/s00268-001-0196-z.

    Article  PubMed  Google Scholar 

  46. de Jong MC, Mayo SC, Pulitano C, Lanella S, Ribero D, Strub J, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg. 2009;13(12):2141–51. https://doi.org/10.1007/s11605-009-1050-0.

    Article  PubMed  Google Scholar 

  47. Homayounfar K, Bleckmann A, Conradi LC, Sprenger T, Lorf T, Niessner M, et al. Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival. Int J Color Dis. 2013;28(7):1009–17. https://doi.org/10.1007/s00384-013-1648-2.

    Article  CAS  Google Scholar 

  48. Neeff HP, Drognitz O, Holzner P, Klock A, Bronsert P, Hopt UT, et al. Outcome after repeat resection of liver metastases from colorectal cancer. Int J Color Dis. 2013;28(8):1135–41. https://doi.org/10.1007/s00384-013-1670-4.

    Article  Google Scholar 

  49. Salah S, Watanabe K, Park JS, Addasi A, Park JW, Zabaleta J, et al. Repeated resection of colorectal cancer pulmonary oligometastases: pooled analysis and prognostic assessment. Ann Surg Oncol. 2013;20(6):1955–61. https://doi.org/10.1245/s10434-012-2860-y.

    Article  PubMed  Google Scholar 

  50. Luo LX, Yu ZY, Huang JW, Wu H. Selecting patients for a second hepatectomy for colorectal metastases: a systemic review and meta-analysis. Eur J Surg Oncol. 2014;40(9):1036–48. https://doi.org/10.1016/j.ejso.2014.03.012.

    Article  CAS  PubMed  Google Scholar 

  51. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16. https://doi.org/10.1016/S0140-6736(08)60455-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep. 2012;27(6):1849–56. https://doi.org/10.3892/or.2012.1740.

    CAS  PubMed  Google Scholar 

  53. Wang ZM, Chen YY, Chen FF, Wang SY, Xiong B. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: a meta-analysis. Eur J Surg Oncol. 2015;41(9):1197–203. https://doi.org/10.1016/j.ejso.2015.05.020.

    Article  PubMed  Google Scholar 

  54. Araujo RL, Gonen M, Herman P. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis. Ann Surg Oncol. 2015;22(9):3070–8. https://doi.org/10.1245/s10434-014-4354-6.

    Article  PubMed  Google Scholar 

  55. Khoo E, O'Neill S, Brown E, Wigmore SJ, Harrison EM. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford). 2016;18(6):485–93. https://doi.org/10.1016/j.hpb.2016.03.001.

    Article  Google Scholar 

  56. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010;14(11):1691–700. https://doi.org/10.1007/s11605-010-1348-y.

    Article  PubMed  Google Scholar 

  57. Benoist S, Brouquet A, Penna C, Julié C, el Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24(24):3939–45. https://doi.org/10.1200/JCO.2006.05.8727.

    Article  PubMed  Google Scholar 

  58. Bischof DA, Clary BM, Maithel SK, Pawlik TM. Surgical management of disappearing colorectal liver metastases. Br J Surg. 2013;100(11):1414–20. https://doi.org/10.1002/bjs.9213.

    Article  CAS  PubMed  Google Scholar 

  59. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7. https://doi.org/10.1097/01.sla.0000193603.26265.c3.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243–9. https://doi.org/10.1200/JCO.2005.07.740.

    Article  CAS  PubMed  Google Scholar 

  61. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57. discussion 657-648

    Article  PubMed  PubMed Central  Google Scholar 

  62. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15(6):933–9. https://doi.org/10.1093/annonc/mdh217.

    Article  CAS  PubMed  Google Scholar 

  63. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6. https://doi.org/10.1200/JCO.2006.09.0928.

    Article  CAS  PubMed  Google Scholar 

  64. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94(6):798–805. https://doi.org/10.1038/sj.bjc.6603011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103(1):21–30. https://doi.org/10.1093/jnci/djq456.

    Article  PubMed  Google Scholar 

  66. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47. https://doi.org/10.1016/S1470-2045(09)70330-4.

    Article  CAS  PubMed  Google Scholar 

  67. Petrelli F, Barni S. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Color Dis. 2012;27(8):997–1004. https://doi.org/10.1007/s00384-012-1438-2.

    Article  CAS  Google Scholar 

  68. •• Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist. 2016;21(8):988–94. A study that showed that patients with right-sided RAS and BRAF wild-type mCRC seemed to derive no benefit from single-agent anti-EGFRs. https://doi.org/10.1634/theoncologist.2016-0084.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. https://doi.org/10.1056/NEJMoa032691.

    Article  CAS  PubMed  Google Scholar 

  70. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9. https://doi.org/10.1200/JCO.2007.14.9930.

    Article  CAS  PubMed  Google Scholar 

  71. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26(21):3523–9. https://doi.org/10.1200/JCO.2007.15.4138.

    Article  CAS  PubMed  Google Scholar 

  72. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91(3):173–80. https://doi.org/10.1002/jso.20301.

    Article  CAS  PubMed  Google Scholar 

  73. Adam R, Miller R, Pitombo M, Wicherts DA, de Haas RJ, Bitsakou G, et al. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am. 2007;16(3):525–36. https://doi.org/10.1016/j.soc.2007.04.016.

    Article  PubMed  Google Scholar 

  74. Baltatzis M, Chan AK, Jegatheeswaran S, et al. Colorectal cancer with synchronous hepatic metastases: systematic review of reports comparing synchronous surgery with sequential bowel-first or liver-first approaches. Eur J Surg Oncol. 2016;42(2):159–65. https://doi.org/10.1016/j.ejso.2015.11.002.

    Article  CAS  PubMed  Google Scholar 

  75. Chen J, Li Q, Wang C, Zhu H, Shi Y, Zhao G. Simultaneous vs. staged resection for synchronous colorectal liver metastases: a metaanalysis. Int J Color Dis. 2011;26(2):191–9. https://doi.org/10.1007/s00384-010-1018-2.

    Article  Google Scholar 

  76. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28(3):493–508. https://doi.org/10.1200/JCO.2009.23.4450.

    Article  PubMed  Google Scholar 

  77. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–8. https://doi.org/10.1097/SLA.0b013e3181b4539b.

    PubMed  Google Scholar 

  78. Abdalla EK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg. 2009;197(6):737–9. https://doi.org/10.1016/j.amjsurg.2008.06.029.

    Article  PubMed  Google Scholar 

  79. •• Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619–26. This is the first randomized study on the efficacy of RFA in treating metastatic CRC that showed that RFA plus systemic treatment resulted in significant longer PFS compared to systemic chemotherapy alone. https://doi.org/10.1093/annonc/mds053.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. van Duijnhoven FH, Jansen MC, Junggeburt JM, van Hillegersberg R, Rijken AM, van Coevorden F, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol. 2006;13(5):651–8. https://doi.org/10.1245/ASO.2006.08.014.

    Article  PubMed  Google Scholar 

  81. Montgomery RS, Rahal A, Dodd GD 3rd, Leyendecker JR, Hubbard LG. Radiofrequency ablation of hepatic tumors: variability of lesion size using a single ablation device. AJR Am J Roentgenol. 2004;182(3):657–61. https://doi.org/10.2214/ajr.182.3.1820657.

    Article  PubMed  Google Scholar 

  82. Machi J, Uchida S, Sumida K, Limm WM, Hundahl SA, Oishi AJ, et al. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg. 2001;5(5):477–89. https://doi.org/10.1016/S1091-255X(01)80085-8.

    Article  CAS  PubMed  Google Scholar 

  83. Head HW, Dodd GD 3rd, Dalrymple NC, Prasad SR, El-Merhi FM, Freckleton MW, et al. Percutaneous radiofrequency ablation of hepatic tumors against the diaphragm: frequency of diaphragmatic injury. Radiology. 2007;243(3):877–84. https://doi.org/10.1148/radiol.2433060157.

    Article  PubMed  Google Scholar 

  84. Tanabe KK, Curley SA, Dodd GD, Siperstein AE, Goldberg SN. Radiofrequency ablation: the experts weigh in. Cancer. 2004;100(3):641–50. https://doi.org/10.1002/cncr.11919.

    Article  PubMed  Google Scholar 

  85. Pathak S, Jones R, Tang JM, Parmar C, Fenwick S, Malik H, et al. Ablative therapies for colorectal liver metastases: a systematic review. Color Dis. 2011;13:252–65.

    Article  Google Scholar 

  86. Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236(1):132–9. https://doi.org/10.1148/radiol.2361031249.

    Article  PubMed  Google Scholar 

  87. Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer. 2000;89(2):276–84. https://doi.org/10.1002/1097-0142(20000715)89:2<276::AID-CNCR11>3.0.CO;2-0.

  88. Iannitti DA, Martin RC, Simon CJ, Hope WW, Newcomb WL, McMasters KM, et al. Hepatic tumor ablation with clustered microwave antennae: the US phase II trial. HPB (Oxford). 2007;9(2):120–4. https://doi.org/10.1080/13651820701222677.

    Article  Google Scholar 

  89. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17(1):171–8. https://doi.org/10.1245/s10434-009-0686-z.

    Article  PubMed  Google Scholar 

  90. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984;2(5):498–504. https://doi.org/10.1200/JCO.1984.2.5.498.

    Article  CAS  PubMed  Google Scholar 

  91. Hohn DC, Stagg RJ, Price DC, Lewis BJ. Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2′-deoxyuridine. BJ J Clin Oncol. 1985;3(9):1257–60. https://doi.org/10.1200/JCO.1985.3.9.1257.

    Article  CAS  Google Scholar 

  92. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer. 1996;78(8):1639–45. https://doi.org/10.1002/(SICI)1097-0142(19961015)78:8<1639::AID-CNCR1>3.0.CO;2-9.

  93. Kemeny N, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395–403. https://doi.org/10.1200/JCO.2005.03.8166.

    Article  CAS  PubMed  Google Scholar 

  94. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25(35):5649–54. https://doi.org/10.1200/JCO.2007.12.1764.

    Article  PubMed  Google Scholar 

  95. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039–48. https://doi.org/10.1056/NEJM199912303412702.

    Article  CAS  PubMed  Google Scholar 

  96. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.

    CAS  PubMed  Google Scholar 

  97. Martin RC, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58. https://doi.org/10.1002/cncr.29534.

    Article  CAS  PubMed  Google Scholar 

  98. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20. https://doi.org/10.1023/A:1013569329846.

    Article  CAS  PubMed  Google Scholar 

  99. •• van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31. A landmark RCT that showed that the combination of Y90 and systemic chemotherapy resulted in a significantly longer liver-specific PFS when compared to systemic chemotherapy alone. https://doi.org/10.1200/JCO.2015.66.1181.

    Article  PubMed  Google Scholar 

  100. Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141(3):543–53. https://doi.org/10.1007/s00432-014-1833-x.

    Article  CAS  PubMed  Google Scholar 

  101. Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–30. https://doi.org/10.1080/02841860600904854.

    Article  PubMed  Google Scholar 

  102. van der Pool AE, Méndez Romero A, Wunderink W, Heijmen BJ, Levendag PC, Verhoef C, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97(3):377–82. https://doi.org/10.1002/bjs.6895.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Pittsburgh, 3459 Fifth Avenue, Pittsburgh, PA, 15213-2582, USA

    Forat Swaid & Allan Tsung

  2. UPMC Liver Cancer Center, Kaufmann Medical Building, 3471 Fifth Avenue, Suite 300, Pittsburgh, PA, 15213, USA

    Forat Swaid & Allan Tsung

Authors
  1. Forat Swaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Allan Tsung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Forat Swaid.

Ethics declarations

Conflict of Interest

The authors declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Surgery and Surgical Innovations in Colorectal Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Swaid, F., Tsung, A. Current Management of Liver Metastasis From Colorectal Cancer. Curr Colorectal Cancer Rep 14, 12–21 (2018). https://doi.org/10.1007/s11888-018-0397-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-018-0397-6

Keywords

Search

Navigation